Valuation: Physiomics Plc

Market Cap 2.33M 3.17M 2.72M 2.56M 4.4M 303M 4.43M 30.24M 11.72M 153M 11.91M 11.65M 506M P/E 2026 *
-5.15x
P/E 2027 * -
Enterprise Value 2.07M 2.81M 2.41M 2.26M 3.9M 268M 3.92M 26.8M 10.38M 135M 10.55M 10.32M 448M EV / Sales 2026 *
2.07x
EV / Sales 2027 * -
Free-Float
73.34%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Physiomics Plc

Manager TitleAgeSince
Director of Finance/CFO 52 -
Chief Operating Officer - 01/07/2026
Corporate Officer/Principal - 31/08/2021
Director TitleAgeSince
Director/Board Member - 29/04/2026
Chairman 53 29/04/2026
Director/Board Member - 29/04/2026
Change 5-day change 1-year change 3-year change Capi.($)
+0.81%+2.04%-21.18%+11.51% 128B
-0.89%-1.20%-41.88%-18.26% 45.15B
+0.34%+0.01%-1.07%+6.23% 41B
-0.39%-0.58%-22.86%-4.45% 22.54B
-0.66%-2.24%-37.89%-37.55% 18.08B
-0.38%+1.24%-5.04%+6.14% 16.29B
-0.43%-1.36%+2.86%+58.24% 16.28B
-0.22%-0.64%-22.05%-30.96% 10.53B
+0.07%-16.39%+11.95%+39.25% 3.42B
Average -0.21%+2.14%-15.24%+3.35% 33.44B
Weighted average by Cap. +0.12%+3.80%-20.15%+3.25%

Financials

2026 *2027 *
Net sales 1M 1.36M 1.17M 1.09M 1.89M 130M 1.9M 12.96M 5.02M 65.4M 5.1M 4.99M 217M -
Net income -314K -427K -366K -344K -593K -40.7M -595K -4.07M -1.58M -20.53M -1.6M -1.57M -68.01M -
Net Debt -266K -362K -310K -291K -502K -34.48M -504K -3.45M -1.34M -17.4M -1.36M -1.33M -57.62M -
Logo Physiomics Plc
Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.
Employees
-